AstraZeneca Pharmaceuticals LP settled their case against Biovail Corp. over the production of a generic form of AstraZeneca’s bipolar disorder and schizophrenia drug, Seroquel®. Biovail consented not to commercially sell their generic version of the drug until the two patents at issue have expired. The judge also granted AstraZeneca access to some of Biovail’s confidential information for use in their related cases against other pharmaceutical companies who wish to market a generic version of Seroquel®. AstraZeneca is represented by Finnegan.